Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292133 · ClinicalTrials.gov registry record · Phase 2
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03292133: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03292133 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292133, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: * EGF816 * Gefitinib
Interventions
- DRUG Gefitinib
- DRUG EGF816
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2025-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292133
The ClinicalTrials.gov registry entry for NCT03292133 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gefitinib is the first listed.
NCT03292133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03292133 about?
NCT03292133 is a clinical study titled "A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer". This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: * EGF816 * Gefitinib
What is the current status of trial NCT03292133?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-10-31. Estimated completion is 2025-03-04.
What interventions are being tested in trial NCT03292133?
The interventions under investigation include: Gefitinib (DRUG), EGF816 (DRUG).
Who is sponsoring clinical trial NCT03292133?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.